Eli Lilly Reports Strong Q2 2026 Financial Results and Raises Full-Year Guidance

Details

The company raised its full-year revenue guidance to a range of $85.0 billion to $87.0 billion and updated its non-GAAP EPS guidance to $35.50 to $36.50, reflecting strong underlying business growth offset by acquired IPR&D charges. Regulatory progress included approvals for Ebglyss and Jaypirca, and the submission for orforglipron for type 2 diabetes. Business development activities included several acquisitions to expand the company's pipeline and manufacturing capacity.

Items reported

About Eli Lilly and Company

Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.